Drug Intake and Actinic Keratosis: A Case-Control Study

Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated. Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrea Sechi, Ambra Di Altobrando, Eugenio Cerciello, Elisa Maietti, Annalisa Patrizi, Francesco Savoia
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	drug reaction photosensitivity actinic keratosis angiotensin receptor blockers antiplatelet drug Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/cb25d78c75d14e6a8f309058e2703433
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb25d78c75d14e6a8f309058e2703433
record_format	dspace
spelling	oai:doaj.org-article:cb25d78c75d14e6a8f309058e27034332021-11-17T08:27:59ZDrug Intake and Actinic Keratosis: A Case-Control Study10.5826/dpc.1102a312160-9381https://doaj.org/article/cb25d78c75d14e6a8f309058e27034332021-04-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1515https://doaj.org/toc/2160-9381 Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated. Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of AK. A secondary aim was to identify a possible association between any medication other than those primarily examined and AK. Methods: A single-center, case-control study assessed the cumulative drug exposure of 90 patients with AK and 90 controls visiting a dermatology service for other skin ailments. Before the visit, patients were interviewed to collect data on daily therapy and the lag-time of discontinued drugs within the last 2 years, and to record the drug’s active ingredient, dosage, and duration of therapy. In addition, sociodemographic characteristics including age, sex, educational level, skin phototype, and cumulative sun exposure habits were gathered. Results: By logistic regression, exposures to angiotensin II receptor blockers (ARBs) and antiplatelet agents were identified as independent risk factors for the development of AK. ARB intake was associated with AK only at high exposure (OR = 13.6; 95% CI, 2.0-93.8). The use of antiplatelet drugs was borderline, yet not significant, at low exposure (OR = 3.31; 95% CI, 0.86-12.7), but increased in a dose-dependent manner. The strongest correlation was found at the highest cumulative dose (>1100 dose unit-years (OR = 4.38; 95% CI, 1.16-16.6). Conclusions: High exposure to ARBs and antiplatelet agents may promote AK carcinogenesis in at-risk patients. Andrea SechiAmbra Di AltobrandoEugenio CercielloElisa MaiettiAnnalisa PatriziFrancesco SavoiaMattioli1885articledrug reactionphotosensitivityactinic keratosisangiotensin receptor blockersantiplatelet drugDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 11, Iss 2 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug reaction photosensitivity actinic keratosis angiotensin receptor blockers antiplatelet drug Dermatology RL1-803
spellingShingle	drug reaction photosensitivity actinic keratosis angiotensin receptor blockers antiplatelet drug Dermatology RL1-803 Andrea Sechi Ambra Di Altobrando Eugenio Cerciello Elisa Maietti Annalisa Patrizi Francesco Savoia Drug Intake and Actinic Keratosis: A Case-Control Study
description	Background: Actinic keratosis (AK) is a form of premalignant keratinocyte dysplasia. Recently, the role of photosensitizing drugs in the development of AK has been postulated. Objective: This study evaluated a possible association between the use of photosensitizing drugs and the development of AK. A secondary aim was to identify a possible association between any medication other than those primarily examined and AK. Methods: A single-center, case-control study assessed the cumulative drug exposure of 90 patients with AK and 90 controls visiting a dermatology service for other skin ailments. Before the visit, patients were interviewed to collect data on daily therapy and the lag-time of discontinued drugs within the last 2 years, and to record the drug’s active ingredient, dosage, and duration of therapy. In addition, sociodemographic characteristics including age, sex, educational level, skin phototype, and cumulative sun exposure habits were gathered. Results: By logistic regression, exposures to angiotensin II receptor blockers (ARBs) and antiplatelet agents were identified as independent risk factors for the development of AK. ARB intake was associated with AK only at high exposure (OR = 13.6; 95% CI, 2.0-93.8). The use of antiplatelet drugs was borderline, yet not significant, at low exposure (OR = 3.31; 95% CI, 0.86-12.7), but increased in a dose-dependent manner. The strongest correlation was found at the highest cumulative dose (>1100 dose unit-years (OR = 4.38; 95% CI, 1.16-16.6). Conclusions: High exposure to ARBs and antiplatelet agents may promote AK carcinogenesis in at-risk patients.
format	article
author	Andrea Sechi Ambra Di Altobrando Eugenio Cerciello Elisa Maietti Annalisa Patrizi Francesco Savoia
author_facet	Andrea Sechi Ambra Di Altobrando Eugenio Cerciello Elisa Maietti Annalisa Patrizi Francesco Savoia
author_sort	Andrea Sechi
title	Drug Intake and Actinic Keratosis: A Case-Control Study
title_short	Drug Intake and Actinic Keratosis: A Case-Control Study
title_full	Drug Intake and Actinic Keratosis: A Case-Control Study
title_fullStr	Drug Intake and Actinic Keratosis: A Case-Control Study
title_full_unstemmed	Drug Intake and Actinic Keratosis: A Case-Control Study
title_sort	drug intake and actinic keratosis: a case-control study
publisher	Mattioli1885
publishDate	2021
url	https://doaj.org/article/cb25d78c75d14e6a8f309058e2703433
work_keys_str_mv	AT andreasechi drugintakeandactinickeratosisacasecontrolstudy AT ambradialtobrando drugintakeandactinickeratosisacasecontrolstudy AT eugeniocerciello drugintakeandactinickeratosisacasecontrolstudy AT elisamaietti drugintakeandactinickeratosisacasecontrolstudy AT annalisapatrizi drugintakeandactinickeratosisacasecontrolstudy AT francescosavoia drugintakeandactinickeratosisacasecontrolstudy
_version_	1718425829186207744

Drug Intake and Actinic Keratosis: A Case-Control Study

Ejemplares similares